Anti-reflux therapy and mortality in patients with idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a systematic review and meta-analysis
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3349 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Konstantinos Dodos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Physiology, School of Medicine, Aristotle University of Thessaloniki. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Idiopathic Pulmonary Fibrosis, Proton Pump Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Gastroesophageal reflux disease (GERD) and idiopathic pulmonary fibrosis (IPF) frequently coexist, with GERD potentially exacerbating IPF progression through microaspiration and pulmonary inflammation. This systematic review and meta-analysis assessed the impact of anti-reflux therapy, including proton pump inhibitors and H2-receptor antagonists, on mortality outcomes in IPF patients with concurrent GERD. A systematic search identified six eligible studies, including 2874 patients, for quantitative synthesis. Results indicate that anti-reflux therapy may reduce IPF-related mortality, with a pooled relative risk (RR) of 0.79 [95% confidence interval (CI): 0.55-1.33], although this finding was not statistically significant. However, no significant effect was observed on overall mortality (pooled RR: 0.97, 95% CI: 0.74-1.25). Study heterogeneity was moderate (I2=60%), reflecting variability in study designs, populations, and therapeutic regimens. The observational nature of most studies highlights the need for randomized controlled trials to better understand anti-reflux therapy’s role in IPF management. While anti-reflux therapy was associated with a potential reduction in IPF-related mortality (RR: 0.79, 95% CI: 0.55-1.33), no significant effect on overall mortality was observed (RR: 0.97, 95% CI: 0.74-1.25). Future research should also evaluate the long-term safety of anti-reflux therapy, given concerns about complications such as infections and renal impairment. This analysis underscores the importance of tailored treatment approaches in IPF patients with GERD to optimize clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Physiology, School of Medicine, Aristotle University of Thessaloniki.
- Department of Biochemistry, Sismanogleio Hospital, Athens.
- Department of Pulmonology and Allergology, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau.
- Department of Pathophysiology, Laiko General Hospital, National and Kapodistrian University of Athens.
ORCID-Profile: Konstantinos Dodos, Nikolaos Trakas, Alexandru Corlateanu, Vasiliki Epameinondas Georgakopoulou
Zitieren
APA
Dodos, K., Kalamara, T. V., Trakas, N., Corlateanu, A., & Georgakopoulou, V. E. (2025). Anti-reflux therapy and mortality in patients with idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a systematic review and meta-analysis. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3349
Vancouver
Dodos K, Kalamara TV, Trakas N, Corlateanu A, Georgakopoulou VE. Anti-reflux therapy and mortality in patients with idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a systematic review and meta-analysis. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3349
BibTeX
@article{Dodos2025,
author = {Dodos, Konstantinos and Kalamara, Tsampika-Vasileia and Trakas, Nikolaos and Corlateanu, Alexandru and Georgakopoulou, Vasiliki Epameinondas},
title = {Anti-reflux therapy and mortality in patients with idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a systematic review and meta-analysis},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3349}
}
EUVIMED